DRG Market Assessment 보고서

With the availability of over a dozen disease-modifying therapies (DMTs) to treat multiple sclerosis (MS), the treatment journey for MS patients is varied and complex. To date, the MS market…

Pelvic pain is the main clinical manifestation associated with endometriosis, a disorder caused by endometrial tissues growing outside the uterus. Pain relievers, hormonal contraceptives, aromatase…

Human immunodeficiency virus (HIV) is treatment is typically initiated with daily administration of costly yet highly effective antiretroviral therapies from multiple drug classes in order to…

Recent launches of Merck & Co.’s Lusduna (insulin glargine) in Europe, and Eli Lilly/Boehringer Ingelheim’s Basaglar (insulin glargine) in the United States, have expanded the non-innovator…

There have been significant economic benefits in Europe since the approval of the first biosimilar more than a decade ago. Although the first FDA biosimilar approval was in 2015, biosimilars are…

Two of the largest pharmacy benefits managers (PBMs) in the United States, Express Scripts and CVS Health, have set traditional U.S. drug reimbursement on its head by introducing indication-…

Market Outlook: Many cases of hospital-acquired infections and healthcare-associated illnesses are attributable to C. difficile infection (CDI). Although standard-of-care antibiotics are…

Graft versus host disease (GVHD) is a potentially life-threatening complication of allogenic hematopoietic stem-cell transplants (HSCTs). The systemic inflammatory reaction is triggered by donor T…

MARKET OUTLOOK Bipolar disorder (BPD) is a debilitating psychiatric illness that is increasingly considered to be a spectrum disorder. Patients experience symptoms ranging in severity from…

In April 2017, Truxima (rituximab), Celltrion’s biosimilar of Roche’s MabThera, became the first oncology monoclonal antibody (MAb) biosimilar to enter the European market. In this series, we…

Faced with the financial pressures of reimbursing a robust pipeline of new and expensive cancer therapies, U.S. managed care organizations (MCOs) are increasing their focus on managing the…

Inflectra (infliximab-dyyb), Pfizer/Celltrion’s Remicade biosimilar, became the first monoclonal antibody biosimilar to enter the U.S. market in late November 2016. In this series, we track…